Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neisseria meningitidis Infections - Overview
Neisseria meningitidis Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neisseria meningitidis Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
Neisseria meningitidis Infections - Drug Profiles
Neisseria meningitidis Infections - Dormant Projects
Neisseria meningitidis Infections - Discontinued Products
Neisseria meningitidis Infections - Product Development Milestones
Featured News & Press Releases
Jan 08, 2022: CanSinoBIO announces approval for its MCV4 product Menhycia in Chi
Sep 27, 2021: New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline including MenQuadfi and commitment to advancing public health protection
Jul 12, 2021: Sanofi’s meningococcal disease jab meets all endpoints in Phase III trial
Jan 15, 2021: Microsuper-biological tetravalent meningococcal conjugate vaccine formally submitted for IND application
Nov 23, 2020: European Commission approves MenQuadfi, the latest innovation in meningococcal (MeCWY) vaccition for individuals 12 months of age and older
Sep 17, 2020: Sanofi receives CHMP positive opinion for MenQuadfi intended for prophylaxis against invasive meningococcal disease
Jun 22, 2020: Pfizer announces start of Phase 3 Clinical Trial of MeBCWY
May 29, 2020: The European Medicines Agency has filised its assessment of an application to extend the use of Trumenba for the prevention of invasive meningococcal disease
Aug 29, 2019: $440 million funding boost for vital health and medical research for all stages of life
Nov 28, 2018: NIHR supports world-first trial of new nose drop to fight meningitis
Jun 27, 2018: European approval for lower dose of GSk’s Meningitis vaccine
Jun 18, 2018: New way to determine protection of Men B vaccine against different strains
Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Desigtion for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Cada
Feb 07, 2018: GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Desigtion from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Neisseria meningitidis Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Neisseria meningitidis Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Neisseria meningitidis Infections - Pipeline by AIM Vaccine Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Alopexx Inc, 2022
Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Biological E Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Bioworld Technologies Sdn Bhd, 2022
Neisseria meningitidis Infections - Pipeline by CanSino Biologics Inc, 2022
Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Eubiologics Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by GSK plc, 2022
Neisseria meningitidis Infections - Pipeline by Hilleman Laboratories Pvt Ltd, 2022
Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Intravacc BV, 2022
Neisseria meningitidis Infections - Pipeline by Inventprise LLC, 2022
Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, 2022
Neisseria meningitidis Infections - Pipeline by Lanzhou Institute of Biological Products Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Neoculi Pty Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Novo Medi Sciences Pvt Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Omvax Inc, 2022
Neisseria meningitidis Infections - Pipeline by Pfizer Inc, 2022
Neisseria meningitidis Infections - Pipeline by ReAlta Life Sciences Inc, 2022
Neisseria meningitidis Infections - Pipeline by Sanofi, 2022
Neisseria meningitidis Infections - Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2022
Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, 2022
Neisseria meningitidis Infections - Dormant Projects, 2022
Neisseria meningitidis Infections - Dormant Projects, 2022 (Contd..2)
Neisseria meningitidis Infections - Discontinued Products, 2022